142 related articles for article (PubMed ID: 15102669)
1. Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer.
Woelfle U; Sauter G; Santjer S; Brakenhoff R; Pantel K
Clin Cancer Res; 2004 Apr; 10(8):2670-4. PubMed ID: 15102669
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors.
Menz A; Weitbrecht T; Gorbokon N; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Hinsch A; Höflmayer D; Weidemann S; Fraune C; Möller K; Bernreuther C; Lebok P; Clauditz T; Sauter G; Uhlig R; Wilczak W; Steurer S; Minner S; Burandt E; Krech R; Dum D; Krech T; Marx A; Simon R
Mol Med; 2021 Feb; 27(1):16. PubMed ID: 33588765
[TBL] [Abstract][Full Text] [Related]
3. Keratin expression in breast cancers.
Shao MM; Chan SK; Yu AM; Lam CC; Tsang JY; Lui PC; Law BK; Tan PH; Tse GM
Virchows Arch; 2012 Sep; 461(3):313-22. PubMed ID: 22851038
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of glycodelin in breast cancer correlates with estrogen-receptor alpha and progesterone-receptor A positivity.
Scholz C; Toth B; Barthell E; Mylonas I; Weissenbacher T; Friese K; Jeschke U
Histol Histopathol; 2009 Apr; 24(4):467-71. PubMed ID: 19224449
[TBL] [Abstract][Full Text] [Related]
5. Tubulolobular carcinoma of the breast: an analysis of 27 cases of a tumor with a hybrid morphology and immunoprofile.
Wheeler DT; Tai LH; Bratthauer GL; Waldner DL; Tavassoli FA
Am J Surg Pathol; 2004 Dec; 28(12):1587-93. PubMed ID: 15577677
[TBL] [Abstract][Full Text] [Related]
6. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
7. Expression of cytokeratin messenger RNA versus protein in the normal mammary gland and in breast cancer.
Su L; Morgan PR; Lane EB
Hum Pathol; 1996 Aug; 27(8):800-6. PubMed ID: 8760013
[TBL] [Abstract][Full Text] [Related]
8. Cytokeratin expression patterns as an indicator of tumour progression in oesophageal squamous cell carcinoma.
Cintorino M; Tripod SA; Santopietro R; Antonio P; Lutfi A; Chang F; Syrjänen S; Shen Q; Tosi P; Syrjänen K
Anticancer Res; 2001; 21(6A):4195-201. PubMed ID: 11911318
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological parameters and biological markers predicting non-sentinel node metastasis in sentinel node-positive breast cancer patients.
Kwon Y; Ro J; Kang HS; Kim SK; Hong EK; Khang SK; Gong G; Ro JY
Oncol Rep; 2011 Apr; 25(4):1063-71. PubMed ID: 21258771
[TBL] [Abstract][Full Text] [Related]
10. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
Rosen PP; Lesser ML; Arroyo CD; Cranor M; Borgen P; Norton L
J Clin Oncol; 1995 Apr; 13(4):821-30. PubMed ID: 7707107
[TBL] [Abstract][Full Text] [Related]
11. NKD1 down-regulation is associated with poor prognosis in breast invasive ductal carcinoma.
Lv ZD; Zhang L; Liu XP; Jin LY; Dong Q; Li FN; Wang HB; Kong B
Int J Clin Exp Pathol; 2015; 8(4):4015-21. PubMed ID: 26097589
[TBL] [Abstract][Full Text] [Related]
12. Expression of glycodelin in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastases.
Shabani N; Mylonas I; Kunert-Keil C; Briese V; Janni W; Gerber B; Friese K; Jeschke U
Anticancer Res; 2005; 25(3A):1761-4. PubMed ID: 16033096
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of cytokeratin 18 enhances BCRP-mediated multidrug resistance through induction of epithelial-mesenchymal transition and predicts poor prognosis in breast cancer.
Shi R; Wang C; Fu N; Liu L; Zhu D; Wei Z; Zhang H; Xing J; Wang Y
Oncol Rep; 2019 May; 41(5):3015-3026. PubMed ID: 30896886
[TBL] [Abstract][Full Text] [Related]
14. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
15. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
16. Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features.
Palacios J; Benito N; Pizarro A; Suárez A; Espada J; Cano A; Gamallo C
Am J Pathol; 1995 Mar; 146(3):605-12. PubMed ID: 7534041
[TBL] [Abstract][Full Text] [Related]
17. Survivin expression in breast lobular carcinoma: correlations with normal breast tissue and clinicomorphological parameters.
Adamkov M; Výbohová D; Horáček J; Kovalská M; Furjelová M
Acta Histochem; 2013 Jun; 115(5):412-7. PubMed ID: 23219440
[TBL] [Abstract][Full Text] [Related]
18. COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
Miglietta A; Toselli M; Ravarino N; Vencia W; Chiecchio A; Bozzo F; Motta M; Torchio B; Bocca C
Expert Opin Ther Targets; 2010 Jul; 14(7):655-64. PubMed ID: 20536410
[TBL] [Abstract][Full Text] [Related]
19. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells.
Willipinski-Stapelfeldt B; Riethdorf S; Assmann V; Woelfle U; Rau T; Sauter G; Heukeshoven J; Pantel K
Clin Cancer Res; 2005 Nov; 11(22):8006-14. PubMed ID: 16299229
[TBL] [Abstract][Full Text] [Related]
20. Cytokeratin expression in malignant melanoma: potential application of in-situ hybridization analysis of mRNA.
Chen N; Gong J; Chen X; Xu M; Huang Y; Wang L; Geng N; Zhou Q
Melanoma Res; 2009 Apr; 19(2):87-93. PubMed ID: 19190520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
